Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Retained Earnings (2022 - 2025)

Mangoceuticals' Retained Earnings history spans 4 years, with the latest figure at -$40.6 million for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 103.19% to -$40.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$40.6 million, a 103.19% decrease, with the full-year FY2025 number at -$40.6 million, down 103.19% from a year prior.
  • Retained Earnings hit -$40.6 million in Q4 2025 for Mangoceuticals, down from -$37.9 million in the prior quarter.
  • Over the last five years, Retained Earnings for MGRX hit a ceiling of -$70.0 in Q1 2024 and a floor of -$40.6 million in Q4 2025.
  • Historically, Retained Earnings has averaged -$14.6 million across 4 years, with a median of -$8.7 million in 2023.
  • Biggest five-year swings in Retained Earnings: surged 100.0% in 2024 and later tumbled 37057022.86% in 2025.
  • Tracing MGRX's Retained Earnings over 4 years: stood at -$2.0 million in 2022, then plummeted by 457.02% to -$11.2 million in 2023, then tumbled by 78.16% to -$20.0 million in 2024, then crashed by 103.19% to -$40.6 million in 2025.
  • Business Quant data shows Retained Earnings for MGRX at -$40.6 million in Q4 2025, -$37.9 million in Q3 2025, and -$31.6 million in Q2 2025.